Skip to main content

Allan Douglas Kirk, MD, PhD

David C. Sabiston, Jr. Distinguished Professor of Surgery
Chair, Department of Surgery
Professor of Surgery
Professor in Pediatrics
Professor in the Department of Immunology
Campus Mail: DUMC 3704, Durham, NC 27710

I am a surgeon with interest in immune management of transplant recipients. I am particularly interested in therapies that influence T cell costimulation pathways and adjuvant therapies that facilitate costimulation blockade to prevent the rejection of transplanted organs without undue suppression of protective immunity. I am also interested in understanding how injury, such as that occurring during trauma or in elective surgery, influences immune responses and subsequent healing following injury.

Costimulation Blockade in Organ Transplantion

Allan D. Kirk, MD, PhD, Department of Surgery Chairman
David C. Sabiston, Jr. Professor of Surgery

Education and Training

  • Fellow, Multi Organ Transplantation, University of Wisconsin, Madison, 1995 - 1997
  • Chief Resident, Surgery, Duke University, 1994 - 1995
  • Senior Resident, Surgery, Duke University, 1992 - 1994
  • Research Fellow, Surgery, Duke University, 1989 - 1992
  • Intern & Junior Resident, Surgery, Duke University, 1987 - 1989
  • Ph.D., Duke University, 1992
  • M.D., Duke University School of Medicine, 1987
  • B.S., Old Dominion University, 1983

Selected Grants

Publications

Bradley, J. A., W. M. Baldwin, A. Bingaman, C. Ellenrieder, H. M. Gebel, D. Glotz, and A. D. Kirk. “Antibody-mediated rejection--an ounce of prevention is worth a pound of cure.” Am J Transplant 11, no. 6 (June 2011): 1131–39. https://doi.org/10.1111/j.1600-6143.2011.03581.x.

Full Text

Thompson, P., K. Cardona, M. Russell, I. R. Badell, V. Shaffer, G. Korbutt, G. R. Rayat, et al. “CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates.” Am J Transplant 11, no. 5 (May 2011): 947–57. https://doi.org/10.1111/j.1600-6143.2011.03509.x.

Full Text

Kim, E. J., J. Kwun, A. J. Page, F. Leopardi, A. C. Gibby, A. D. Kirk, and S. J. Knechtle. “A Non-Human Primate Model for Alloantibody Production after T Cell Depletion.” In American Journal of Transplantation, 11:369–369. WILEY-BLACKWELL, 2011.

Scholars@Duke

Lo, D. J., T. Weaver, F. Leopardi, M. Song, A. B. Farris, N. A. Turgeon, A. K. Mehta, C. P. Larsen, and A. D. Kirk. “Adjuvant Treatment with Alefacept (LFA-3-Ig) Promotes Belatacept-Based Immunomodulation in Renal Transplantation in Nonhuman Primates.” In American Journal of Transplantation, 11:172–73. WILEY-BLACKWELL, 2011.

Scholars@Duke

Kim, E. J., J. Kwun, A. J. Page, F. Leopardi, A. C. Gibby, A. D. Kirk, and S. J. Knechtle. “Alefacept Overcomes Memory T Cell Barrier after T Cell Depletion with a Novel Recombinant CD3-Immunotoxin (A-DmDT390-ScfbDb) in a Non-Human Primate Renal Transplantation Model.” In American Journal of Transplantation, 11:453–453. WILEY-BLACKWELL, 2011.

Scholars@Duke

Xu, H., A. K. Mehta, S. Mead, J. Cheeseman, L. Stempora, T. C. Pearson, C. Larsen, and A. D. Kirk. “Belatacept, but Not Calcineurin Inhibitors, Preserve Human CMV-Specific Memory Cell Responses.” In American Journal of Transplantation, 11:44–44. WILEY-BLACKWELL, 2011.

Scholars@Duke

Ferrer, I. R., M. E. Wagener, M. Song, A. D. Kirk, M. L. Ford, and C. P. Larsen. “CD40/CD154 Pathway Blockade Mediates Conversion of Antigen-Specific CDC+ T Cells into FoxP3(+) Cells and Inhibits CD8(+) T Cell Effector Function.” In American Journal of Transplantation, 11:342–342. WILEY-BLACKWELL, 2011.

Scholars@Duke

Mehta, A. K., M. McCausland, D. J. Lo, J. Joseph, J. Cheeseman, R. Elbein, T. Gourley, et al. “Chronic Kidney Disease and CMV Drive Patient Specific Pre-Transplant Immune Deviations Toward Terminal Differentiation and Exhaustion.” In American Journal of Transplantation, 11:388–388. WILEY-BLACKWELL, 2011.

Scholars@Duke

Pages